Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals (NASDAQ: ABOS) operates at the intersection of neuroscience research and clinical drug development, making its news particularly relevant for investors tracking Alzheimer's disease therapeutics. As a clinical-stage biopharmaceutical company targeting amyloid-beta oligomers, Acumen generates news tied directly to scientific milestones and regulatory progress.
News coverage for Acumen typically includes clinical trial updates such as patient enrollment progress, study design announcements, and data readouts from ongoing trials. The company also announces research presentations at medical conferences where scientists share findings on drug candidates and disease biology. These conference presentations often precede or accompany peer-reviewed publications.
Partnership announcements represent another important news category for Acumen. Collaborations with other pharmaceutical companies, academic institutions, or contract research organizations can expand the company's development capabilities and validate its therapeutic approach. Such deals may include licensing agreements, research collaborations, or manufacturing partnerships.
Financial news includes quarterly earnings reports detailing cash position and research spending, which are critical metrics for pre-revenue biotechnology companies. Capital raises, public offerings, and financing transactions directly impact the company's ability to fund ongoing clinical programs.
Tracking Acumen's news flow provides insight into the progress of Alzheimer's disease research and the clinical development timeline for oligomer-targeting therapies. Bookmark this page to follow material developments as they occur.
Acumen Pharmaceuticals has developed a synthetic model for soluble amyloid beta oligomers (AβOs), crucial for Alzheimer’s disease research. This model aims to standardize assays for AβOs, which have been challenging to study due to their complexity. The methodology will be presented at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. The ongoing Phase 1 clinical trial of ACU193, targeting toxic AβOs, is expected to yield important data to advance Alzheimer’s research.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced its participation in two upcoming major conferences focusing on Alzheimer's disease. At the Alzheimer’s Association International Conference (AAIC) in San Diego, the company will present a poster on August 3, 2022, detailing their research on amyloid beta oligomers. Additionally, Dr. Eric Siemers, Chief Medical Officer, will speak at the BTIG Biotech Conference on August 8, 2022, discussing next-generation therapeutics targeting Alzheimer's pathology. Acumen is advancing its investigational product ACU193, a monoclonal antibody in Phase 1 trials.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2022 financial results, highlighting a cash balance of $216.7 million as of March 31, 2022, sufficient to fund operations through 2025. The company is advancing its Phase 1 clinical trial, INTERCEPT-AD, for its drug ACU193 targeting early Alzheimer’s disease, with topline data expected in the first half of 2023. R&D expenses increased to $6.0 million from $2.6 million YoY, reflecting ongoing trial costs. Acumen's net loss for the quarter was $9.1 million, a decrease from $27.0 million in Q1 2021.
Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q1 2022 financial results on May 16, 2022, at 4:30 PM ET. The company will host a conference call and a live audio webcast to discuss business performance and financial updates. Acumen is focused on developing a novel therapy for Alzheimer’s disease, specifically targeting toxic AβOs through its investigational drug, ACU193, currently in Phase I trials. Interested investors can access the live webcast via the company’s website.
Acumen Pharmaceuticals (NASDAQ: ABOS) announces publication in Frontiers in Neuroscience of preclinical evidence supporting ACU193, a monoclonal antibody targeting amyloid beta oligomers for early Alzheimer's disease treatment. The publication indicates that AβO-mediated neuronal toxicity contributes to cognitive impairments in Alzheimer's patients. Key findings include ACU193's selectivity towards AβOs without binding to plaques, suggesting a reduced risk of amyloid-related imaging abnormalities. Ongoing Phase I clinical trials aim to validate these findings and explore ACU193's therapeutic potential.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported progress on ACU193, its monoclonal antibody targeting toxic amyloid-beta oligomers, currently in Phase 1 clinical trial INTERCEPT-AD for early Alzheimer's patients. The trial has experienced slower enrollment due to COVID-19, but topline results are expected in H1 2023. Acumen ended 2021 with $225.9 million in cash, sufficient to fund operations through 2025. The company's leadership was strengthened with new appointments, including Kim Drapkin to the Board. Net losses were $100.6 million in 2021, primarily due to non-cash expenses related to fair value changes.
Acumen Pharmaceuticals (ABOS) will report its financial results for Q4 and full year 2021 on March 28, 2022, at 4:30 PM ET. The company is focused on developing targeted therapeutics for Alzheimer’s disease, particularly its investigational drug ACU193, an immunotherapy targeting toxic AβOs, currently in a Phase I clinical trial. This conference call will update stakeholders on business and financial matters, with access available via the company’s website.
Acumen Pharmaceuticals, focusing on Alzheimer’s disease therapeutics, achieved a significant milestone by enrolling the first patients in the INTERCEPT-AD Phase 1 clinical trial for its investigational drug, ACU193. This humanized monoclonal antibody selectively targets toxic amyloid-beta oligomers (AβOs). Despite delays attributed to the COVID-19 Delta variant, Acumen expects to report topline data by the end of 2022. The company reported a net loss of $92.3 million for the nine-month period ending September 30, 2021, with cash and cash equivalents totaling $135.8 million.
Acumen Pharmaceuticals, a clinical stage biopharmaceutical company focused on Alzheimer's disease, announced participation in two upcoming virtual conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 9:40 AM EST, followed by the Stifel 2021 Healthcare Conference on November 16, 2021, at 10:00 AM EST. Live webcasts will be accessible on-demand for 30 days after each event on their website. Acumen is advancing its investigational product ACU193, targeting toxic AβOs in early Alzheimer's patients.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced its participation in the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference, where it will present on its investigational drug ACU193. This monoclonal antibody targets toxic amyloid-beta oligomers, a key factor in Alzheimer’s disease pathology. The INTERCEPT-AD trial, currently enrolling early Alzheimer’s patients, aims to assess safety and cognitive improvements. The presentation is scheduled for November 10, 2021, and emphasizes ACU193's potential to modify disease progression with improved synaptic function.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
